Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + PD-1 inhibitor + chemotherapy vs PD-1 inhibitor + chemotherapy in R/M HNSCC
ChiCTR2600128985Phase 3Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jul 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab, pembrolizumab, finotonlimab, paclitaxel, cisplatin and 1 more in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression Free Survival (PFS). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600128985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128985.